DrugPatentWatch Database Preview
Drugs in Development Information for Dalcetrapib
» See Plans and Pricing
What is the drug development status for Dalcetrapib?
Dalcetrapib is an investigational drug.
There have been 14 clinical trials for Dalcetrapib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Coronary Disease, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are Hoffmann-La Roche, DalCor Pharmaceuticals, and The Montreal Health Innovations Coordinating Center (MHICC).
There are one hundred and fifty-seven US patents protecting this investigational drug and two international patents.
Summary for Dalcetrapib
| US Patents | 157 |
| International Patents | 2,446 |
| US Patent Applications | 291 |
| WIPO Patent Applications | 1,296 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 73 |
Recent Clinical Trials for Dalcetrapib
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | Covance | Phase 2 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | The Montreal Health Innovations Coordinating Center (MHICC) | Phase 2 |
| Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19 | DalCor Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Dalcetrapib
Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib
US Patents for Dalcetrapib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dalcetrapib | Start Trial | Pharmaceutical compositions with enhanced performance and improved processability | HERCULES LLC (Wilmington, DE) | Start Trial |
| Dalcetrapib | Start Trial | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | Hoffmann-La Roche Inc. (Little Falls, NJ) | Start Trial |
| Dalcetrapib | Start Trial | CETP activity inhibitors | Japan Tobacco Inc. (Tokyo, JP) | Start Trial |
| Dalcetrapib | Start Trial | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE) | Start Trial |
| Dalcetrapib | Start Trial | CETP activity inhibitor | Japan Tobacco Inc. (Tokyo, JP) | Start Trial |
| Dalcetrapib | Start Trial | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE) | Start Trial |
| Dalcetrapib | Start Trial | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dalcetrapib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dalcetrapib | Brazil | BR112015021179 | 2033-03-01 | Start Trial |
| Dalcetrapib | Canada | CA2899546 | 2033-03-01 | Start Trial |
| Dalcetrapib | China | CN105073783 | 2033-03-01 | Start Trial |
| Dalcetrapib | European Patent Office | EP2961775 | 2033-03-01 | Start Trial |
| Dalcetrapib | Japan | JP2016510080 | 2033-03-01 | Start Trial |
| Dalcetrapib | Japan | JP6456849 | 2033-03-01 | Start Trial |
| Dalcetrapib | South Korea | KR20150125655 | 2033-03-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
